Edwards Lifesciences

EWleader

Edwards Lifesciences is the global leader in transcatheter heart valve therapies, particularly TAVR, which has transformed treatment for aortic stenosis from open-heart surgery to a catheter-based procedure.

⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($6.4B)

Static data (loading live financials…)

Transcatheter Aortic Valve (60%)

Surgical Structural Heart (15%)

Critical Care (15%)

TMTT (10%)

Segment Breakdown & Key Customers

Product Details

TAVR (SAPIEN)60%

Transcatheter aortic valve replacement systems for heart valve disease

TMTT10%

Transcatheter mitral and tricuspid valve therapies in development

Surgical Structural Heart15%

Surgical heart valves and repair products

Critical Care15%

Hemodynamic monitoring and smart recovery technologies

Supply Chain Relationships

Competitors

Medtronic

CoreValve TAVR system

Impact: Primary TAVR competitor

Abbott Laboratories

Structural heart portfolio

Impact: Growing competitor in structural heart

Boston Scientific

ACURATE valve

Impact: Emerging TAVR competitor

Macro & Market Context

헬스케어Sector News

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Upcoming Catalysts

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of Edwards Lifesciences.

Company Info

Headquarters

Irvine, California, USA

Founded

1958

Employees

20,000+

Website

edwards.com

Sector Overview — 헬스케어

Sector News